Travoprost Ophthalmic Solution, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. Lupin has received approval from ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The phase 3 trial investigated a fast-eluting and a slow ...
iDose TR is expected to be available in the first quarter of 2024. The Food and Drug Administration (FDA) has approved iDose ® TR (travoprost intracameral implant) for the reduction of intraocular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results